Evolva to receive first milestone payment from Roche
Evolva Holding SA announced that Roche has confirmed that Evolva has achieved its first milestone in their collaboration. Roche will now make a corresponding milestone payment (of an undisclosed amount) to Evolva. The milestone relates to the achievement of diverse, purified active compounds that derive from Evolva’s synthetic biology platform. The milestone payment does not change Evolva’s cash flow guidance for 2011.
The aim of Evolva’s collaboration with Roche is to use Evolva’s technology platform to create compounds with activity on targets in oncology and infectious disease. The project commenced in January 2010.
Neil Goldsmith, CEO and Managing Director of Evolva, said “The collaboration with Roche is progressing well. Our platform is delivering on its promise to fundamentally change multiple industries. After recent successes in nutritional ingredients, it is great to see the potential in pharmaceuticals further confirmed.”
Organizations
Other news from the department business & finance

Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.